A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface

Molecular Cancer Therapeutics

Volumn 12, Issue 4, 2013, Pages 416-426

  Tang, Zhewei ^a,b   Feng, Mingqian ^b   Gao, Wei ^b   Phung, Yen ^b   Chen, Weizao ^c   Chaudhary, Amit ^d   Croix, Brad St ^d   Qian, Min ^a   Dimitrov, Dimiter S ^c   Ho, Mitchell ^b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Structural Glycobiology Section   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; EPITOPE; FC RECEPTOR; MESOTHELIN; SD1 HFC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; COMPLEMENT DEPENDENT CYTOTOXICITY; EPIDERMAL CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; GPI-LINKED PROTEINS; HUMANS; MICE; NEOPLASMS; PROTEIN BINDING; SINGLE-DOMAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876478787     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0731     Document Type: Article

References (40)

1. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52: 181-6.
2. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40. (Pubitemid 26041483)
3. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53. (Pubitemid 350262830)
4. Ho M. Advances in liver cancer antibody therapies: a focus on glypi-can-3 and mesothelin. Biodrugs 2011;25:275-84.
5. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borqhaei H, et al. Mesothelin, a novle immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 2012;133:799-804.
6. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65. (Pubitemid 43980544)
7. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007;7:20.
8. Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 2011;128: 2020-30.
9. Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 2009;8:1113-8.
10. Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009;284:3739-49.
11. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10: 317-27.
12. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of ritux-imab in vivo. J Immunol 2003;171:1581-7. (Pubitemid 36900094)
13. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-43. (Pubitemid 38393032)
14. Pawluczkowycz AW, Beursken FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183:749-58
15. Mossner E, Brunker P, Moser S, Punterner U, Schmidit C, Herter S, et al. Increasing the efficacy of CD20 antibody by therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402
16. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117: 4519-29.
17. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, et al. New monoclonal antibodies to mesothelin useful for immunohistochemis-try, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005;11:5840-6. (Pubitemid 41170311)
18. Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, et al. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 2010;1:141-9.
19. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20. (Pubitemid 40685601)
20. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008;382:779-89.
21. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005;280:607-17. (Pubitemid 40165027)
22. Ho M, Pastan I. In vitro antibody affinity maturation targeting germline hotspots. Methods Mol Biol 2009;525:293-308
23. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccinesinmice and nonhuman primates. J Virol 2005;79:8828-34 (Pubitemid 40934793)
24. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydro-phobicity of its heavy chain third complementarity-determining region. J Virol 2010;84:2955-62.
25. Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008;68:2400-8. (Pubitemid 351521815)
26. Xiang X, Feng M, Felder M, Connor JP, Man YG, Patankar MS, et al. HN125: a novel immunoadhesin targeting MUC16 with potential for cancer therapy. J Cancer 2011;2:280-91.
27. Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, et al. TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 2012;21:212-26.
28. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increase cellular immunotoxins uptake. Cancer Res 2010;70:1082-9.
29. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13:1571-5. (Pubitemid 46450449)
30. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010;16:6132-8.
31. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT00570713. [cited July 13, 2012].
32. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT00738582. [cited July 13, 2012].
33. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 2012;11:517-25.
34. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitor. Nat Biotechnol 1999;17:568-72. (Pubitemid 29262920)
35. Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Isolation of monoclonal antibody fragments from phage display libraries. Methods Mol Biol 2009;502:341-64.
36. Ho M, Nagata S, Pastan I. Isolation of anti-CD22 Fc with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A 2006;103: 9637-42. (Pubitemid 43955877)
37. Jiang Y, Li F, Zha D, Potgieter TI, Mithcell T, Moore R, et al. Purification process development of a recombinant monoclonal antibody expressed in glycoengineered Pichia pastoris. Protein Expr Purif 2011; 76:7-14.
38. Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A 2010;107:604-9.
39. Chan CE, Lim AP, Chan AH, MacAry PA, Hanson BJ. Optimized expression of full-length IgG1 antibody in a common E. coli strain. PLoS ONE 2012;5:e10261.
40. Stork R, Zettlitz KA, Muller D, Rether M, Hanisch FG, Kontermann RE. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008;283: 7804-12.